What is Somahlution?
Somahlution is positioned within the biotechnology sector, with a specific focus on developing innovative healthcare solutions and medical advancements. The company's core offering includes DuraGraft Technology, recognized as the first FDA-cleared solution for the preservation of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) procedures. This technology is designed to mitigate oxidative damage and enhance graft cell viability, aiming to deliver superior outcomes compared to conventional storage methods. The primary market for Somahlution's innovations comprises healthcare providers and institutions engaged in cardiac surgery.
How much funding has Somahlution raised?
Somahlution has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Somahlution?
The substantial late-stage funding received by Somahlution signals a critical juncture for the company, likely enabling accelerated expansion of its commercial reach and further research and development initiatives. With a focus on scaling, Somahlution is poised to enhance its market presence and potentially introduce additional advancements in cardiovascular care. The strategic investment is expected to fuel operational growth, bolster its competitive position, and support the broader adoption of its groundbreaking DuraGraft Technology within the healthcare ecosystem.
See full Somahlution company page
